Effects of fluvastatin on LDL peroxidation and photon emission of the aorta in cholesterol-fed rabbits

[1]  K. Satake,et al.  Chemiluminescence properties of soybean protein fraction in the hydroperoxide and hydrogen donor system. , 1999, Luminescence : the journal of biological and chemical luminescence.

[2]  M. Yasuhara,et al.  Superoxide anion scavenging properties of fluvastatin and its metabolites. , 1999, Chemical & pharmaceutical bulletin.

[3]  J. Widimský,et al.  The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. , 1999, Atherosclerosis.

[4]  M. Yasuhara,et al.  Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. , 1999, Biochemical pharmacology.

[5]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[6]  O. Hussein,et al.  Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. , 1997, Atherosclerosis.

[7]  K. Okubo,et al.  Mechanism of catechin chemiluminescence in the presence of active oxygen. , 1996, Journal of bioluminescence and chemiluminescence.

[8]  T. Kanazawa,et al.  Protective effects of soy protein on the peroxidizability of lipoproteins in cerebrovascular diseases. , 1995, The Journal of nutrition.

[9]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[10]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[11]  P. Steinbrecher.  Role of lipoprotein peroxidation in the pathogenesis of atherosclerosis , 1991, Clinical cardiology.

[12]  T. Kanazawa,et al.  Acceleration of platelet aggregability due to modulation of native LDL. , 1990, Circulation research.

[13]  D. Ayer,et al.  Novel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation. , 1988, Biochemical pharmacology.

[14]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Chait,et al.  Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. , 1986, The Journal of clinical investigation.

[16]  P. Serruys,et al.  A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.

[17]  T. Kanazawa,et al.  Evaluation of oxidized low-density lipoprotein and large molecular size low-density lipoproteins in atherosclerosis. , 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.

[18]  J L Witztum,et al.  The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. , 1992, Annual review of medicine.

[19]  S. Ylä-Herttuala,et al.  Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. , 1991, Annals of medicine.

[20]  H. Kaneko.  The Causes of the Arteriosclerosis: -Internalization of Ultra-Water-Soluble LDLs into Mouse Peritoneal Macrophages and their Cell Injury Potential-@@@―超水可溶性LDLのマウス腹腔マクロファージへの取り込みとその細胞傷害性について― , 1990 .